Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman for the prediction of the expectant mother's risk of delivering spontaneously. It is also developing a pipeline of novel blood-based biomarker tests for major pregnancy-related conditions, including time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

Sera Prognostics Inc.

Sera Prognostics, Inc. ( ($SERA) ) has released its Q3 earnings. Here is a breakdown of the information Sera Prognostics, Inc. presented to its inv...

Market Cap	$139.69M	P/E Ratio	N/A
52W High	$9.13	52W Low	$1.37
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	24.8%	52W Position	27.6%
Overall Score	68	Value Score	80
Quality Score	44	Technical Score	81

EPS Current Est	$-0.68	EPS Next Est	$-0.74
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SERA	$3.51	+3.24%	132.67K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SERA	$3.51	+3.2%	132.67K
3
4
5
6

SERA

SERA

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Sera Prognostics Inc. Data in Excel

Get Sera Prognostics Inc. Data in Excel